Literature DB >> 10944658

The stimulants revisited.

T E Wilens1, T J Spencer.   

Abstract

Stimulants are the most often prescribed psychotropics in children and adolescents, used generally for the treatment of attention deficit/hyperactivity disorder (ADHD). In this article the authors summarize the literature on prevalence of usage, neurobiology, and pharmacology of the stimulants. Recent studies on the use of stimulants in special ADHD populations including preschoolers and adults, and co-occurring neurologic, psychiatric, and substance use disorders are cited. Clinical guidelines for the management of individuals receiving the stimulants are offered, and treatment strategies delineated for ADHD subjects with comorbidity and medication-induced adverse effects are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10944658

Source DB:  PubMed          Journal:  Child Adolesc Psychiatr Clin N Am        ISSN: 1056-4993


  36 in total

Review 1.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

2.  New developments in the treatment of attention-deficit/hyperactivity disorder in primary care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

3.  Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.

Authors:  Wen-Jiun Chou; Shin-Jaw Chen; Ying-Sheue Chen; Hsin-Yi Liang; Chih-Chien Lin; Ching-Shu Tang; Yu-Shu Huang; Chin-Bin Yeh; Miao-Chun Chou; Dai-Yueh Lin; Po-Hsun Hou; Yu-Yu Wu; Hung-Jen Liu; Ya-Fen Huang; Kai-Ling Hwang; Chin-Hong Chan; Chia-Ho Pan; Hsueh-Ling Chang; Chi-Fen Huang; Ju-Wei Hsu
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-04-26       Impact factor: 2.576

Review 4.  Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.

Authors:  James C Ermer; Ben A Adeyi; Michael L Pucci
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

5.  Inattention symptoms predict level of depression in early childhood.

Authors:  Khushmand Rajendran; Sarah O'Neill; Jeffrey M Halperin
Journal:  Postgrad Med       Date:  2013-01       Impact factor: 3.840

Review 6.  Non-stimulant medications in the treatment of ADHD.

Authors:  Tobias Banaschewski; Veit Roessner; Ralf W Dittmann; Paramala Janardhanan Santosh; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

Review 7.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

8.  Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression?

Authors:  W Burleson Daviss; Boris Birmaher; Rasim S Diler; James Mintz
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-06       Impact factor: 2.576

9.  Atomoxetine: a novel treatment for child and adult ADHD.

Authors:  Marcialee Ledbetter
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

Review 10.  Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants.

Authors:  Jan Buitelaar; Rossella Medori
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-10-13       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.